# IGF-1 LR3 Peptide

> IGF-1 LR3 is a modified IGF-1 analog that reduces IGF-binding protein attachment and prolongs IGF-style growth and repair signaling.

Canonical: https://pepflow.app/peptides/igf-1-lr3/

The Long IGF Analog

IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems.

Muscle repair  Tissue recovery

Tier D

Evidence Preliminary

Safety Limited Data

FDA status Not Approved

Last reviewed October 25, 2026 23 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is IGF-1 LR3?

IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)

That design makes the molecule biologically interesting, but it also separates it from prescription growth-hormone products and from normal circulating IGF-1 physiology. The key issue is whether this specific analog has route-matched human outcome and safety evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)

Product labels often collapse IGF-1, IGF-1 LR3, and research-grade IGF analogs into one category. Those products need separation because potency, binding-protein behavior, exposure, and anti-doping status can differ.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) For more context, read the [IGF-1 LR3 explainer](<https://pepflow.app/blog/igf-1-lr-3/>).

## What IGF-1 LR3 is investigated for

IGF-1 LR3 evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Extended IGF-axis signaling Injectable 45% Preliminary

Extended IGF-axis signaling is the clearest LR3 mechanism, but it should not be translated into a safe or proven human muscle-growth protocol.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9415072/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/8708565/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

#### Human evidence

No controlled human LR3 trial establishes that extended IGF-axis signaling improves a clinical or training outcome.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9415072/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/8708565/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)

#### Animal / mechanistic evidence

Animal studies of IGF-I analogs that bind poorly to IGF-binding proteins report more potent and prolonged biological effects than native IGF-I.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9415072/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/8708565/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)

### ### Muscle growth and recovery support Injectable 30% Limited

Muscle-growth and recovery claims remain preclinical and mixed, not established lean-mass or recovery therapy.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

#### Human evidence

No controlled human outcome trials for IGF-1 LR3 muscle growth or training recovery were identified in the cited literature.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

#### Animal / mechanistic evidence

Animal work connects long R3 IGF-1 with protein metabolism and somatotropic-axis signaling, while a fetal-sheep growth study did not show a growth benefit.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

### ### Training recovery support Injectable 24% Limited

Training recovery is distinct from muscle growth, while both remain indirect and preclinical.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

#### Human evidence

No controlled human IGF-1 LR3 training-recovery outcome trials were identified in the cited literature.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

#### Animal / mechanistic evidence

Animal protein-metabolism and somatotropic-axis studies provide the recovery rationale, but they do not directly prove post-training repair or performance recovery.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/9252489/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

## Evidence snapshot

### Overall confidence

Preliminary

40%

IGF-1 LR3 has plausible IGF-axis activity, but controlled human outcome and safety data for this analog are thin. Muscle and recovery evidence remains separate from prescription growth-hormone or native IGF-1 evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

15%

### Human evidence

Insufficient

No direct controlled human outcome evidence establishes IGF-1 LR3 for muscle growth, recovery, or body composition. Human relevance is inferred from adjacent IGF-axis literature rather than product-specific results.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

30%

### Animal / preclinical

Limited

Laboratory and animal evidence supports IGF-axis activity and binding-protein differences. Translation to practical injectable outcomes remains uncertain.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

40%

### Mechanism support

Preliminary

The analog is designed for persistent IGF-1 receptor activity with reduced binding-protein constraint. That mechanism can affect protein synthesis, glucose handling, and cell-survival pathways, which explains both interest and caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## Forms & administration

IGF-1 LR3 is offered in injectable research-market products. Nasal delivery remains experimental, with animal-only evidence and no established human regimen. Both forms require their own preparation and exposure assessment, separate from prescription IGF-1 medicines.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/39610283/>)

Injectable Nasal spray

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 20-50 mcg per dose.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

### Frequency

Usually taken daily or on training days.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

### Timing Considerations

Common timing is morning or after a workout.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

### Cycle Length

Common cycles run 4-6 weeks.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

[Full IGF-1 LR3 dosage guide](<https://pepflow.app/peptides/igf-1-lr3/dosage/>)

## What to expect

### First 1-2 weeks

Injectable/systemic IGF-axis exposure may show up as fuller training pumps, appetite shifts, body-weight water movement, and glucose-pattern changes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

### Weeks 4-6

Injectable/systemic recovery, training load, waist, body weight, and lean-mass appearance may settle into a clearer pattern.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

### After stopping

Pump, fullness, and recovery signals may soften after injectable IGF-1 LR3 exposure ends, while training and nutrition determine whether body-composition changes hold.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)

## Safety profile

IGF-1 LR3 safety centers on systemic IGF-axis exposure: glucose symptoms, fluid shifts, growth-factor biology, injectable quality, and sport status matter more than ordinary injection comfort.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### Common side effects

- Appetite change [\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Fluid retention [\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Glucose symptoms [\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### Cautions

- Cancer-biology context[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Diabetes / glucose control[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Prohibited in sport[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### What we don't know

Human dose-response, immunogenicity, long-term metabolic effects, and product interchangeability remain poorly characterized for IGF-1 LR3.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Who IGF-1 LR3 is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for IGF-1 LR3.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)
- **Active cancer or unexplained growths**

  Active cancer or unexplained growths warrants medical review or avoidance for IGF-1 LR3.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)
- **Diabetes or hypoglycemia risk without clinician oversight**

  Diabetes or hypoglycemia risk without clinician oversight warrants medical review or avoidance for IGF-1 LR3.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Insulin / glucose-lowering drugs**

  Insulin, sulfonylureas, or other glucose-lowering drugs can intensify or mask glucose symptoms during IGF-axis exposure; this is a GH/insulin-axis caution.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **GH-axis products**

  Somatropin, GHRPs, or GH secretagogues can stack IGF-axis exposure, edema, and glucose effects; this is a theoretical pathway caution.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **Anabolic hormones**

  Testosterone, anabolic agents, or strong bulking stacks can compound edema and growth-signal tracking; this is a theoretical pathway caution.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, IGF-1 LR3 has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · IGF-1 LR3 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · IGF-1 LR3 is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Approved

IGF-1 LR3 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

IGF-1 LR3 is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[16\]](<https://www.ema.europa.eu/en/medicines>) [\[17\]](<https://products.mhra.gov.uk/>) [\[18\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[19\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S2 applies to IGF-1 and related growth-factor activity; tested athletes should not treat injectable IGF-1 LR3 as athlete-cleared without a valid TUE or anti-doping review.[\[11\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

IGF-1 LR3 is an IGF-1 analog designed for longer, less binding-protein-constrained IGF-1 receptor signaling than native IGF-1. That receptor pathway can push protein synthesis, glucose handling, cell survival, and tissue-growth signals, which explains the bodybuilding interest and the endocrine risk.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

The route caveat is central because the page is about injectable systemic exposure, not a food supplement or approved replacement product. Persistent IGF-axis signaling can overlap with glucose control, organ-growth, cancer-biology, and anti-doping concerns, so product identity and dose matter more than the shorthand name.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## Research gaps & open questions

What the current literature has not yet settled about IGF-1 LR3:

01

Controlled trials need to study IGF-1 LR3 itself—not standard IGF-1—and show whether it changes muscle growth, fat loss, strength, or recovery in people.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

02

Studies need to show how each route changes exposure and how often IGF-1 LR3 causes low blood sugar or longer-term glucose problems.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

03

Independent testing needs to establish whether research-market products contain authentic IGF-1 LR3 at the labeled strength and are free of important impurities.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## Common questions

### Is IGF-1 LR3 FDA-approved?

No. IGF-1 LR3 has no U.S. FDA approval for injectable drug use; 503A compounding status and WADA concerns are separate issues.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

### Is IGF-1 LR3 the same as IGF-1?

No. It is a modified IGF-1 analog designed for different binding-protein and exposure behavior, so native IGF-1 evidence does not automatically transfer.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

### Is IGF-1 LR3 proven for muscle growth?

Not proven. Human muscle-growth outcomes for injectable IGF-1 LR3 are not established; the mechanism also raises glucose and growth-signal safety concerns.[\[9\]](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>) [\[10\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)

## Myths & misconceptions

### Myth

IGF-1 LR3 is just another growth-hormone peptide.

### Reality

It sits downstream in IGF-style signaling and has different metabolic and safety questions from GH secretagogues.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

### Myth

Longer IGF-style signaling makes it better.

### Reality

Longer or stronger pathway activity can also raise exposure and safety concerns.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## History & discovery

Long R3 IGF-1 entered the literature as a modified IGF-axis research tool, not as a finished medicine. The modification made it useful for studying IGF receptor signaling when ordinary binding proteins complicate interpretation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

Animal and metabolic studies used IGF-1 LR3 to probe protein metabolism, glucose handling, and growth-factor signaling. That shaped later performance-market interest, but it did not create a controlled human muscle-growth program.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

Detection work on a black-market Long R3 IGF-I product shifted the story toward identity, purity, and anti-doping concerns. Market visibility therefore became a safety and enforcement issue, not clinical validation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39679943/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/37114757/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10370861/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)

## Published research 23 citations

- [\[1\] **IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.** Am J Physiol Endocrinol Metab, 2025 Jan 1. animal.](<https://pubmed.ncbi.nlm.nih.gov/39679943/>)
- [\[2\] **Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.** J Dev Orig Health Dis, 2023 Jun. animal.](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)
- [\[3\] **Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.** Domest Anim Endocrinol, 1999 May. animal.](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)
- [\[4\] **IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.** J Endocrinol, 1997 Nov. animal.](<https://pubmed.ncbi.nlm.nih.gov/9415072/>)
- [\[5\] **Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.** J Endocrinol, 1996 Jul. animal.](<https://pubmed.ncbi.nlm.nih.gov/8708565/>)
- [\[6\] **Detection of His-tagged Long-R³-IGF-I in a black market product.** Growth Horm IGF Res, 2010 Oct. review.](<https://pubmed.ncbi.nlm.nih.gov/20675162/>)
- [\[7\] **The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.** Am J Physiol, 1997 Jul. animal.](<https://pubmed.ncbi.nlm.nih.gov/9252489/>)
- [\[8\] **Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.** J Alzheimers Dis, 2025 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/39610283/>)
- [\[9\] **Drugs@FDA/openFDA query for IGF-1 LR3** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22IGF-1%20LR3%22&limit=1>)
- [\[10\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[11\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[12\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[13\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[14\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[15\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[16\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[17\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[18\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[19\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[20\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[21\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[22\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[23\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

D

**Evidence**

40% Preliminary

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[23 citations](<https://pepflow.app/peptides/igf-1-lr3/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Extended IGF-axis signaling
- Muscle growth and recovery support
- Training recovery support

### Common side effects

- Appetite change
- Fluid retention
- Glucose symptoms

### Also known as

- Long R3 IGF-1
- Long arginine 3 IGF-I
- LR3 IGF-I
- IGF-1 Long R3

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [IGF 1 Lr 3: IGF 1 LR3](<https://pepflow.app/blog/igf-1-lr-3/>)
- [IGF-1 LR3 dosage guide](<https://pepflow.app/peptides/igf-1-lr3/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
